<p>赛诺菲（纳斯达克股票代码：SNY - 获取免费报告）在周二的一份研究报告中，由 StockNews.com 的股票研究人员将其评级从 “买入” 上调至 “强烈买入”。</p>
<ul>
<li>诺和诺德推出 Wegovy，成为三重威胁</li>
</ul>
<p>另外，Argus 将赛诺菲的目标股价从 55.00 美元上调至 60.00 美元，并在 7 月 26 日的一份报告中给予该股票 “买入” 评级。三位分析师对该股票进行了持有评级，两位给出了买入评级，一位给出了强烈买入评级。根据 MarketBeat 的数据，该股票的共识评级为 “中等买入”，共识目标股价为 57.50 美元。</p>
<p><strong>查看我们关于赛诺菲的最新股票报告</strong></p>
<h2>赛诺菲股价表现</h2>
<ul>
<li>6 个购买辉瑞制药股票的理由</li>
</ul>
<p>纳斯达克 SNY 周二上涨 1.27 美元，收于 57.53 美元。该股交易量为 3,561,640 股，相比平均交易量 2,086,575 股有所增加。该公司的 50 天简单移动平均线为 52.23 美元，200 天简单移动平均线为 49.60 美元。该公司的速动比率为 0.65，流动比率为 1.00，负债权益比为 0.17。该公司的市值为 1,457.1 亿美元，市盈率为 28.91，PEG 比为 1.60，贝塔系数为 0.60。赛诺菲的 12 个月最低价为 42.63 美元，最高价为 57.92 美元。</p>
<p>赛诺菲（纳斯达克股票代码：SNY - 获取免费报告）上次公布季度财报是在 7 月 25 日星期四。该公司报告季度每股盈利为 0.93 美元，超过了 0.88 美元的共识预期 0.05 美元。该季度营收为 107.5 亿美元，低于分析师预期的 168.6 亿美元。赛诺菲的净资产回报率为 26.29%，净利润率为 9.60%。公司的营收同比增长了 7.8%。去年同期，公司每股盈利为 0.95 美元。研究分析师预计，赛诺菲本财年的每股盈利将达到 4.23 美元。</p>
<h2>机构投资者对赛诺菲的看法</h2>
<ul>
<li>投资的 20 个最佳医疗保健股票</li>
</ul>
<p>机构投资者最近增加或减少了他们在该股票中的持股。TCTC Holdings LLC 在第一季度将其在赛诺菲的持股增加了 28.0%。TCTC Holdings LLC 现在拥有 960 股该公司的股票，价值 47,000 美元，在上个季度购买了额外的 210 股。HB Wealth Management LLC 在第二季度将其在赛诺菲的持股增加了 3.7%。HB Wealth Management LLC 现在拥有 6,166 股该公司的股票，价值 29,900 美元，在上个季度购买了额外的 221 股。Wynn Capital LLC 在第一季度将其在赛诺菲的持股增加了 4.5%。Wynn Capital LLC 现在拥有 5,266 股该公司的股票，价值 25,600 美元，在上个季度购买了额外的 226 股。Insigneo Advisory Services LLC 在第二季度将其在赛诺菲的持股增加了 3.3%。Insigneo Advisory Services LLC 现在拥有 7,212 股该公司的股票，价值 37,100 美元，在上个季度购买了额外的 228 股。最后，Angeles Investment Advisors LLC 在第四季度将其在赛诺菲的持股增加了 2.1%。Angeles Investment Advisors LLC 现在拥有 12,029 股该公司的股票，价值 59,800 美元，在上个季度购买了额外的 244 股。该股的 10.04% 由机构投资者和对冲基金持有。</p>
<h2>关于赛诺菲（获取免费报告）</h2>
<p>赛诺菲是一家医疗保健公司，从事在美国、欧洲和国际市场的治疗解决方案的研究、开发、制造和营销。它通过制药、疫苗和消费者保健部门运营。该公司提供特殊护理，如 DUPIXENT、神经学和免疫学、罕见疾病、肿瘤学和罕见血液疾病；治疗糖尿病和心血管疾病的药物；以及已建立的处方产品。</p>
<h2>精选故事</h2>
<ul>
<li>我们比赛诺菲更喜欢的五支股票</li>
<li>股市板块：有多少种板块？</li>
<li>内部人正在购买的 3 只小市值股票</li>
<li>什么是 S&amp;P/TSX 指数？</li>
<li>分析师预测西部数据有巨大增长空间——不要错过</li>
<li>投资的不同类型股票</li>
<li>今天市场上必须拥有的 3 只股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U05Z?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U05Z"/></p>
<p><em>这则即时新闻警报是由 Narrative Science 技术和 MarketBeat 的财务数据生成的，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<p>→ 蒂姆·赛克斯的紧急交易警报：“立即采取行动”（来自蒂蒙西赛克斯）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MzE4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MzE4"/></p>
<h2>现在是否值得投资 1,000 美元购买赛诺菲股票？</h2>
<p>在考虑赛诺菲之前，您可能想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级最高和表现最佳的研究分析师以及他们推荐给客户的股票。MarketBeat 已经确定了五支顶级分析师悄悄告诉客户在更广泛市场注意之前购买的股票... 而赛诺菲不在名单上。</p>
<p>虽然赛诺菲目前在分析师中有 “持有” 评级，但顶级分析师认为这五支股票更值得购买。</p>
<p>查看这五支股票</p>

赛诺菲

<p>赛诺菲被 StockNews.com 从"买入"调升至"强烈买入"。此外，Argus 调高了他们对该股票的目标价，目前分析师们普遍认为该股票为"中等买入"。交易量达到了超过 350 万股，赛诺菲的市值约为 847.1 亿美元。公司报告显示，年度营收增长了 7.8%，并超出了本季盈利预期。机构投资者最近也在增加对该公司的持股</p>

<p>Sanofi (NASDAQ:SNY - Get Free Report) was upgraded by equities researchers at StockNews.com from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research report issued to clients and investors on Tuesday.</p>
<ul>
<li>Novo Nordisk Arms Wegovy to Be a Triple Threat</li>
</ul>
<div class="lb-trans"><p>赛诺菲（纳斯达克股票代码：SNY - 获取免费报告）在周二的一份研究报告中，由 StockNews.com 的股票研究人员将其评级从 “买入” 上调至 “强烈买入”。</p>
<ul>
<li>诺和诺德推出 Wegovy，成为三重威胁</li>
</ul>
</div><p>Separately, Argus increased their price objective on Sanofi from $55.00 to $60.00 and gave the stock a &#34;buy&#34; rating in a report on Friday, July 26th. Three analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $57.50.</p>
<div class="lb-trans"><p>另外，Argus 将赛诺菲的目标股价从 55.00 美元上调至 60.00 美元，并在 7 月 26 日的一份报告中给予该股票 “买入” 评级。三位分析师对该股票进行了持有评级，两位给出了买入评级，一位给出了强烈买入评级。根据 MarketBeat 的数据，该股票的共识评级为 “中等买入”，共识目标股价为 57.50 美元。</p>
</div><p><strong>View Our Latest Stock Report on Sanofi</strong></p>
<div class="lb-trans"><p><strong>查看我们关于赛诺菲的最新股票报告</strong></p>
</div><h2>Sanofi Price Performance</h2>
<ul>
<li>6 reasons to buy Teva Pharmaceuticals stock sooner than later</li>
</ul>
<div class="lb-trans"><h2>赛诺菲股价表现</h2>
<ul>
<li>6 个购买辉瑞制药股票的理由</li>
</ul>
</div><p>NASDAQ SNY traded up $1.27 on Tuesday, reaching $57.53. 3,561,640 shares of the stock traded hands, compared to its average volume of 2,086,575. The firm's fifty day simple moving average is $52.23 and its 200 day simple moving average is $49.60. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. The company has a market cap of $145.71 billion, a price-to-earnings ratio of 28.91, a P/E/G ratio of 1.60 and a beta of 0.60. Sanofi has a 12 month low of $42.63 and a 12 month high of $57.92.</p>
<div class="lb-trans"><p>纳斯达克 SNY 周二上涨 1.27 美元，收于 57.53 美元。该股交易量为 3,561,640 股，相比平均交易量 2,086,575 股有所增加。该公司的 50 天简单移动平均线为 52.23 美元，200 天简单移动平均线为 49.60 美元。该公司的速动比率为 0.65，流动比率为 1.00，负债权益比为 0.17。该公司的市值为 1,457.1 亿美元，市盈率为 28.91，PEG 比为 1.60，贝塔系数为 0.60。赛诺菲的 12 个月最低价为 42.63 美元，最高价为 57.92 美元。</p>
</div><p>Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings data on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.05. The business had revenue of $10.75 billion during the quarter, compared to analyst estimates of $16.86 billion. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. The company's revenue was up 7.8% compared to the same quarter last year. During the same period last year, the company posted $0.95 EPS. As a group, research analysts predict that Sanofi will post 4.23 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>赛诺菲（纳斯达克股票代码：SNY - 获取免费报告）上次公布季度财报是在 7 月 25 日星期四。该公司报告季度每股盈利为 0.93 美元，超过了 0.88 美元的共识预期 0.05 美元。该季度营收为 107.5 亿美元，低于分析师预期的 168.6 亿美元。赛诺菲的净资产回报率为 26.29%，净利润率为 9.60%。公司的营收同比增长了 7.8%。去年同期，公司每股盈利为 0.95 美元。研究分析师预计，赛诺菲本财年的每股盈利将达到 4.23 美元。</p>
</div><h2>Institutional Investors Weigh In On Sanofi</h2>
<ul>
<li>20 best healthcare dividend stocks to invest in</li>
</ul>
<div class="lb-trans"><h2>机构投资者对赛诺菲的看法</h2>
<ul>
<li>投资的 20 个最佳医疗保健股票</li>
</ul>
</div><p>Institutional investors have recently added to or reduced their stakes in the stock. TCTC Holdings LLC raised its position in Sanofi by 28.0% in the 1st quarter. TCTC Holdings LLC now owns 960 shares of the company's stock worth $47,000 after purchasing an additional 210 shares during the last quarter. HB Wealth Management LLC increased its position in shares of Sanofi by 3.7% in the 2nd quarter. HB Wealth Management LLC now owns 6,166 shares of the company's stock valued at $299,000 after buying an additional 221 shares in the last quarter. Wynn Capital LLC increased its position in shares of Sanofi by 4.5% in the 1st quarter. Wynn Capital LLC now owns 5,266 shares of the company's stock valued at $256,000 after buying an additional 226 shares in the last quarter. Insigneo Advisory Services LLC increased its position in shares of Sanofi by 3.3% in the 2nd quarter. Insigneo Advisory Services LLC now owns 7,212 shares of the company's stock valued at $371,000 after buying an additional 228 shares in the last quarter. Finally, Angeles Investment Advisors LLC increased its position in shares of Sanofi by 2.1% in the 4th quarter. Angeles Investment Advisors LLC now owns 12,029 shares of the company's stock valued at $598,000 after buying an additional 244 shares in the last quarter. 10.04% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>机构投资者最近增加或减少了他们在该股票中的持股。TCTC Holdings LLC 在第一季度将其在赛诺菲的持股增加了 28.0%。TCTC Holdings LLC 现在拥有 960 股该公司的股票，价值 47,000 美元，在上个季度购买了额外的 210 股。HB Wealth Management LLC 在第二季度将其在赛诺菲的持股增加了 3.7%。HB Wealth Management LLC 现在拥有 6,166 股该公司的股票，价值 29,900 美元，在上个季度购买了额外的 221 股。Wynn Capital LLC 在第一季度将其在赛诺菲的持股增加了 4.5%。Wynn Capital LLC 现在拥有 5,266 股该公司的股票，价值 25,600 美元，在上个季度购买了额外的 226 股。Insigneo Advisory Services LLC 在第二季度将其在赛诺菲的持股增加了 3.3%。Insigneo Advisory Services LLC 现在拥有 7,212 股该公司的股票，价值 37,100 美元，在上个季度购买了额外的 228 股。最后，Angeles Investment Advisors LLC 在第四季度将其在赛诺菲的持股增加了 2.1%。Angeles Investment Advisors LLC 现在拥有 12,029 股该公司的股票，价值 59,800 美元，在上个季度购买了额外的 244 股。该股的 10.04% 由机构投资者和对冲基金持有。</p>
</div><h2>About Sanofi (Get Free Report)</h2>
<div class="lb-trans"><h2>关于赛诺菲（获取免费报告）</h2>
</div><p>Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.</p>
<div class="lb-trans"><p>赛诺菲是一家医疗保健公司，从事在美国、欧洲和国际市场的治疗解决方案的研究、开发、制造和营销。它通过制药、疫苗和消费者保健部门运营。该公司提供特殊护理，如 DUPIXENT、神经学和免疫学、罕见疾病、肿瘤学和罕见血液疾病；治疗糖尿病和心血管疾病的药物；以及已建立的处方产品。</p>
</div><h2>Featured Stories</h2>
<ul>
<li>Five stocks we like better than Sanofi</li>
<li>Stock Market Sectors: What Are They and How Many Are There?</li>
<li>3 Small Cap Stocks That Insiders Are Buying</li>
<li>What is the S&amp;P/TSX Index?</li>
<li>Analysts Forecast Big Upside for Western Digital—Don’t Miss Out</li>
<li>There Are Different Types of Stock To Invest In</li>
<li>3 Must-Own Stocks for Bullish Investors in Today's Market</li>
</ul>
<div class="lb-trans"><h2>精选故事</h2>
<ul>
<li>我们比赛诺菲更喜欢的五支股票</li>
<li>股市板块：有多少种板块？</li>
<li>内部人正在购买的 3 只小市值股票</li>
<li>什么是 S&amp;P/TSX 指数？</li>
<li>分析师预测西部数据有巨大增长空间——不要错过</li>
<li>投资的不同类型股票</li>
<li>今天市场上必须拥有的 3 只股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U05Z" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=SNY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由 Narrative Science 技术和 MarketBeat 的财务数据生成的，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><p>→ Tim Sykes’ Urgent Trade Alert: “Make this move now” (From Timothy Sykes)(Ad)</p>
<div class="lb-trans"><p>→ 蒂姆·赛克斯的紧急交易警报：“立即采取行动”（来自蒂蒙西赛克斯）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MzE4" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9318&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Sanofi right now?</h2>
<div class="lb-trans"><h2>现在是否值得投资 1,000 美元购买赛诺菲股票？</h2>
</div><p>Before you consider Sanofi, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑赛诺菲之前，您可能想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级最高和表现最佳的研究分析师以及他们推荐给客户的股票。MarketBeat 已经确定了五支顶级分析师悄悄告诉客户在更广泛市场注意之前购买的股票... 而赛诺菲不在名单上。</p>
</div><p>While Sanofi currently has a &#34;Hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然赛诺菲目前在分析师中有 “持有” 评级，但顶级分析师认为这五支股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五支股票</p>
</div>

赛诺菲（NASDAQ:SNY）在 StockNews.com 被上调至强力买入评级